The <scp>OtR</scp> tumor recurrence and metastasis model reveals doxorubicin‐induced tumor shrinkage doesn't guarantee prolonged survival
Collectively, these findings demonstrate that reduced tumor growth in preclinical mouse models does not necessarily translate into overall survival benefit. Our results emphasize the critical importance of prioritizing metastasis prevention over tumor growth inhibition as a key efficacy endpoint in antitumor drug evaluation.
Authors
- Minyao Deng
- Cheng Liu
- X W Li
- Lingli Luo
- Ling Liu (ORCID: https://orcid.org/0009-0007-6355-9660)
- Yong Jiang
- Xiang Chen
Institutions
- Jiangsu University (CN)
- Nanchang University (CN)
- Shanghai Jiao Tong University (CN)
- Third Affiliated Hospital of Nanchang University (CN)
- Third Hospital of Nanchang (CN)
- Shanghai First People's Hospital (CN)
- Yixing Tumor Hospital (CN)
- Yixing People's Hospital (CN)
Publication Details
- Journal
- Animal Models and Experimental Medicine
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/ame2.70127
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00